Global Multiple Myeloma Drugs Market 2017-2021

Global multiple myeloma drugs market forecast

According to the multiple myeloma drugs industry analysis, the global multiple myeloma drugs market will grow at a CAGR of over 9% between 2017 and 2021. The market is currently witnessing a paradigm shift towards the implementation of proteasome inhibitors as a key therapeutic strategy in the treatment of multiple myeloma. Cancer cells have higher levels of proteasome activity are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells, which makes the proteasome a therapeutic target in multiple myeloma. Proteasome inhibitor treatment is preferred after there is a treatment failure with the conventional approach. With the approval of several new proteasome inhibitors, such as Johnson & Johnson's DARZALEX and Takeda Pharmaceuticals' NINLARO, it is expected that the multiple myeloma drugs market value will increase during the forecast period.

Multiple myeloma drugs market drivers

Based on the multiple myeloma drugs market insights, the lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining huge traction in this market, owing to several limitations of existing technologies. The nanotechnology approach allows much earlier diagnosis or treatment regimes and facilitates the delivery of drugs specifically to cancer cells by directing cellular events at the nanometer scale. One of the key clinical benefits of nanocarrier-based approach over conventional drugs is the precise delivery of several chemotherapeutic agents per recognition event. Also, the particulate nanocarriers and polymer conjugates augment the drug portfolio available to oncologists.

Multiple myeloma drugs market growth: Competitive landscape and key vendors

The global multiple myeloma drugs market is characterized by leading companies such as Celgene, Johnson & Johnson, Takeda Pharmaceuticals, Amgen, and Novartis. The advances in research activities and the launch of novel therapies are likely to increase the competition among vendors in the coming years. New players are actively launching drugs for multiple myeloma due to the high unmet medical needs in the market.

Leading vendors in the multiple myeloma drugs market

• Amgen
• Celgene
• Johnson & Johnson
• Novartis
• Takeda Pharmaceuticals

Multiple myeloma drugs market segmentation by therapy

• Biologic therapies
• Targeted therapies
• Chemotherapy

According to the multiple myeloma drugs market outlook, biological therapy drugs use the body's immune system to fight myeloma cells. The biologic therapies are primarily categorized into monoclonal antibodies and immune-modulating agents. These drugs boost the immune system cells that identify and attack cancer cells. The biologic therapies segment is anticipated to benefit from the growing preference among physician to implement biologics owing to their established clinical profile. Also, the approval of new monoclonal antibodies, such as DARZALEX and EMPLICITI, will further drive the growth of this market segment over the next four years. Some of the drugs include THALOMID (thalidomide), REVLIMID (lenalidomide), and POMALYST (pomalidomide).

Multiple myeloma drugs market worth as per geographies

• Americas
• APAC
• EMEA

The Americas led the global market for multiple myeloma drugs in 2016 and will continue its dominance in the market during the forecast period. The constant launch of novel therapies such as NINLARO, DARZALEX, and FARYDAK will considerably drive the growth of the market in the region over the next four years. Also, the label expansion of REVLIMID into new indications such as newly diagnosed multiple myeloma cases is another growth factor for this market in the Americas.

 Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global multiple myeloma drugs market?
• What are the key market trends impacting the growth of the global multiple myeloma drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global multiple myeloma drugs market?
• What are the market opportunities and threats faced by the vendors in the global multiple myeloma drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global multiple myeloma drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Next-Generation Biologics Market 2016-2020